Eplontersen, a late-stage candidate from Ionis Pharmaceuticals (NASDAQ:IONS) and AstraZeneca (NASDAQ:AZN) for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), met all primary and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results